Metfogamma 1000

Metformin Hydrochloride, the active ingredient in Metfogamma 1000, is a biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Metfogamma 1000 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metfogamma 1000, a biguanide antidiabetic, acts on glucose metabolism in type 2 diabetes. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve glycaemic control.

Metfogamma 1000 may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: persistent metallic sensation in the mouth. - Loss of appetite: reduced desire to eat. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic acidosis requiring emergency care. - Severe hypoglycaemia: especially when combined with other glucose‑lowering agents. - Hepatic failure: signs of liver dysfunction. - Allergic reactions: rash, itching, or swelling. - Pancreatitis: abdominal pain with elevated enzymes. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Metfogamma 1000 should be used with caution in several clinical situations. - Renal impairment: assess kidney function before initiating therapy. - Hepatic disease: avoid in patients with significant liver dysfunction. - Congestive heart failure: monitor for fluid overload and lactic acidosis. - Elderly patients: start at lower doses and monitor tolerance. - Vitamin B12 deficiency: periodic monitoring recommended. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Metfogamma 1000 can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis. - Cimetidine: may raise metformin plasma concentrations. - Other antidiabetic agents that cause hypoglycaemia (e.g., sulfonylureas, insulin): risk of severe low blood sugar.

Moderate Interactions (Monitor Closely): - ACE inhibitors and ARBs: monitor renal function and potassium levels. - Diuretics: assess for dehydration and renal function. - Beta‑blockers: may mask hypoglycaemia symptoms. - Corticosteroids: may reduce glycaemic control. - Oral contraceptives: possible alteration of metformin clearance. - Statins: monitor for rare muscle toxicity.